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Summary 46 
Antibodies that target the glycan cap epitope on ebolavirus glycoprotein (GP) are common 47 
in the adaptive response of survivors. A subset is known to be broadly neutralizing, but the details 48 
of their epitopes and basis for neutralization is not well-understood. Here we present cryo-electron 49 
microscopy (cryo-EM) structures of several glycan cap antibodies that variably synergize with GP 50 
base-binding antibodies. These structures describe a conserved site of vulnerability that anchors 51 
the mucin-like domains (MLD) to the glycan cap, which we name the MLD-anchor and cradle. 52 
Antibodies that bind to the MLD-cradle share common features, including the use of IGHV1-69 53 
and IGHJ6 germline genes, which exploit hydrophobic residues and form beta-hairpin structures 54 
to mimic the MLD-anchor, disrupt MLD attachment, destabilize GP quaternary structure and block 55 
cleavage events required for receptor binding. Our results collectively provide a molecular basis 56 
for ebolavirus neutralization by broadly reactive glycan cap antibodies. 57 
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Introduction 69 
There is mounting evidence that protection from filoviral infection can be achieved through 70 
the use of monoclonal antibodies (mAbs) that target the GP surface (Bornholdt et al., 2019; 71 
Brannan et al., 2019; Mire et al., 2017; Qiu et al., 2014; Saphire et al., 2018b). Several structures 72 
of antigen-antibody complexes in recent years indicate that antibodies can access nearly any region 73 
on the surface of GP (Flyak et al., 2015; Flyak et al., 2018; Gilchuk et al., 2018; Milligan et al., 74 
2019; Murin, 2018; Murin et al., 2019; Pallesen et al., 2016; Pascal et al., 2018; Saphire et al., 75 
2018a; Wec et al., 2017; West et al., 2018; Zhao et al., 2017). Such antibodies have utility as post-76 
exposure therapeutics when used in combination, such as the tri-mAb cocktail REGN-EB3, which 77 
demonstrated high efficacy in animal models (Pascal et al., 2018) and in a clinical trial carried out 78 
during a recent Ebola virus (EBOV) outbreak (Mulangu et al., 2019). REGN-EB3 is only effective 79 
against EBOV, however a pan-ebolavirus therapeutic that recognizes multiple ebolaviruses that 80 
cause severe disease in humans and major outbreaks, including Bundibugyo virus (BDBV) and 81 
Sudan virus (SUDV), would be ideal given the unpredictability of ebolavirus outbreaks.  82 
Cross-reactive antibodies often target regions of conserved sequence vital to viral function, 83 
such as the receptor binding site (RBS) (Flyak et al., 2015; Hashiguchi et al., 2015; Howell et al., 84 
2016; King et al., 2018), the internal fusion loop (IFL) (Milligan et al., 2019; Murin, 2018; West 85 
et al., 2018; Zhao et al., 2017), the base of GP (Gilchuk et al., 2018; Misasi et al., 2016) and the 86 
heptad repeat 2 (HR2) region (Bornholdt et al., 2016b; Flyak et al., 2018). Less conserved regions, 87 
such as the glycan cap and MLD, also can be targeted by protective antibodies and typically 88 
represent the largest antibody responses found in survivors; however, such antibodies are usually 89 
weakly or non-neutralizing and species-specific (Murin et al., 2014; Zeitlin et al., 2011). For 90 
example, the antibody 13C6, which was included in the antibody cocktail ZMappTM, targets the 91 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted October 14, 2020. . https://doi.org/10.1101/2020.10.14.340026doi: bioRxiv preprint 
 5 
glycan cap, but is low in potency for viral neutralization and is thought to instead provide 92 
protection by facilitating a superior cellular response (Murin et al., 2014; Pallesen et al., 2016). 93 
Furthermore, the glycan cap/head epitope in the trimeric membrane form of GP is also partially 94 
present on sGP, the soluble dimer of GP that is secreted in abundance during natural infection 95 
(Cook and Lee, 2013; de La Vega et al., 2015; Pallesen et al., 2016). Finally, GP is massively 96 
remodeled during endosomal entry in processes mediated by host proteases, during which the 97 
glycan cap and MLD are removed (Bornholdt et al., 2016a; Lee and Saphire, 2009). Nevertheless, 98 
several antibodies have been identified that bind within the glycan cap and potently neutralize 99 
EBOV, BDBV and SUDV (Bornholdt et al., 2016b; Flyak et al., 2016; Gilchuk et al., 2020; Misasi 100 
et al., 2016; Murin et al., 2014; Pascal et al., 2018; Saphire et al., 2018a). The mechanistic basis 101 
for this activity, however, is not well-explored. 102 
We previously characterized pan-ebolavirus neutralizing mAbs isolated from a survivor 103 
cohort of the EBOV 2013-2016 outbreak (Gilchuk et al., 2018; Gilchuk et al., 2020). Several 104 
antibodies that recognize the glycan cap revealed synergistic activity for the GP binding and virus 105 
neutralization when paired with GP base-binding antibodies. One such pair, EBOV-548 and 106 
EBOV-520, provided superior protection in animal models when compared with treatment by a 107 
single antibody. Structural evaluation revealed that EBOV-520 recognized the 310 pocket that is 108 
partially shielded by the b17- b18 loop in uncleaved GP. EBOV-548, which binds to the glycan 109 
cap, removed this steric hindrance by dislodging and mimicking the b18-b18¢ hairpin obscuring 110 
the 310 pocket. These data revealed a structural mechanism for synergy mediated by a glycan cap-111 
directed antibody. 112 
We sought to determine if glycan cap antibodies from other survivors also use similar 113 
mechanisms of protection and synergy as the EBOV-548/EBOV-520 combination (Bramble et al., 114 
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2018; Flyak et al., 2015; Flyak et al., 2018; Flyak et al., 2016; Gilchuk et al., 2018). This collection 115 
of antibodies, including two mAbs from a newly described survivor cohort, were tested for their 116 
ability to enhance the activity of the GP base-region-binding broadly neutralizing antibodies 117 
EBOV-520 and EBOV-515 (Gilchuk et al., 2020). Additionally, we observed and quantified 118 
antibody-induced GP trimer instability. Subsequent analysis by cryo-EM revealed a conserved 119 
structural motif, similar to that found in EBOV-548, wherein a complementarity determining 120 
region (CDR) exhibited molecular mimicry of the b18-b18¢ hairpin in GP. Finally, we also 121 
quantified the ability of glycan cap antibodies to block GP cleavage events necessary for receptor 122 
binding site exposure. Our data collectively provide evidence for a mechanism behind the activity 123 
of broadly neutralizing and synergistic glycan cap antibodies to ebolaviruses and suggest a rational 124 
strategy for the design of therapeutic antibody cocktails. 125 
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Results 138 
 139 
Glycan cap antibody synergy is a common feature and is associated with GP instability 140 
 We previously described an assay to determine antibody binding synergy of pairs of 141 
antibodies for glycan cap antibody-based synergy of the base-region-binding antibodies EBOV-142 
515 and EBOV-520 (Gilchuk et al., 2020). Here, we extended this assay to glycan cap antibodies 143 
from other survivor cohorts. We chose previously isolated antibodies based on similar properties 144 
to the synergistic glycan cap mAb EBOV-548, including: 1) synergy with EBOV-520 and/or 145 
EBOV-515, 2) broad reactivity and neutralization, 3) long CDRH3 loops, 4) cross-reactivity with 146 
sGP and/or 5) protection in vivo. Based on these criteria, we chose the following antibodies: 147 
BDBV-43, BDBV-329, BDBV-289, EBOV-442, EBOV-437 and EBOV-237 (Flyak et al., 2016; 148 
Gilchuk et al., 2018; Qiu et al., 2012; Williamson et al., 2019; Wilson et al., 2000). EBOV-548, 149 
13C6, and an unrelated human mAb directed to dengue virus (DENV) envelope protein 2D22, 150 
were included for comparative purposes and as controls (Table 1). In addition, we also tested two 151 
new antibodies, EBOV-293 and EBOV-296, which we isolated from an individual treated for 152 
EBOV infection in the United States (Table 1, also see Materials and Methods). Ten characterized 153 
glycan cap antibodies potently bound to the sGP as judged by the half-maximal effective (EC50) 154 
concentrations, and revealed diverse GP reactivity and virus neutralization profiles, and diverse 155 
protective efficacy in EBOV challenge mouse model (Table 1, Fig. S1A). In addition, epitope 156 
mapping by alanine scanning mutagenesis library analysis identified key contact residues for each 157 
antibody (Table 1; Fig. S1B). Furthermore, several of these antibodies have exceptionally long 158 
CDRH3 loops, such as the 33 amino acid loop of BDBV-329 (Table S1). 159 
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 We then analyzed all ten glycan cap mAbs for binding enhancement of the base-region-160 
directed mAbs EBOV-515 or EBOV-520 using an approach described previously (Gilchuk et al., 161 
2020). Synergy for each glycan cap antibody followed similar patterns for EBOV-515 and EBOV-162 
520, although enhancement of EBOV-520 binding appears higher likely due to differences in the 163 
molecular nature of the epitope (Fig. 1A). A steady range of synergistic patterns from no 164 
enhancement (for 13C6) to binding nearly equivalent to cleaved GP (GPCL) (for EBOV-237) were 165 
observed (Fig. 1A). It should be noted that BDBV-329 and EBOV-237 are monospecific for the 166 
autologous virus BDBV or EBOV, respectively (Table 1). 167 
 We noticed in several of our 2D classes of glycan cap antibody complexes that the GP 168 
trimer fell apart into GP monomers, similar to what we had observed with our previous 169 
characterization of EBOV-548 (Gilchuk et al., 2020). The amount of GP trimer destabilization was 170 
variable across all the complexes, with some antibodies inducing a large amount of GP monomers 171 
and others only a stable GP trimer. We specifically avoid inclusion of monomers during protein 172 
purification to obtain a pure fraction of trimeric GP as starting material. We therefore hypothesized 173 
that glycan cap antibodies destabilize trimers, which in turn may contribute to their synergistic 174 
ability with base-region-binding antibodies. 175 
To quantify GP destabilization, we analyzed cryo-EM data collected on glycan cap 176 
antibody complexes for structural analysis (see below). We also included previous data collected 177 
on EBOV-548 complexed with GP (Gilchuk et al., 2020). Particles were selected using a difference 178 
of gaussian approach which would not discriminate trimeric complexes from monomeric ones and 179 
then performed reference-free 2D classification (Fig. 1B). All trimeric and monomeric particles 180 
were subsequently subclassified and particle counts were used to determine the percentage of 181 
monomeric particles in the cleaned stack of total particles for each dataset. 182 
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 When plotting the proportion of monomers formed in the presence of each glycan cap 183 
antibody, we noted that the amount of destabilization correlated with the extent of antibody 184 
synergy (Fig. 1C). Antibodies that did not synergize with base-region-binding antibodies 185 
displayed little to no destabilization, such as 13C6, BDBV-43, BDBV-329 and BDBV-289. As 186 
synergy increased, we saw increasing amounts of destabilized trimers, with EBOV-237 187 
demonstrating the highest level of destabilization (Fig. 1C). 188 
 189 
Conservation of a structural b-hairpin motif across synergistic glycan cap antibodies 190 
To determine the structural basis of neutralization and synergy behind glycan cap antibody-191 
based enhancement of base-region-binding antibodies, we solved eight structures of glycan cap 192 
antibodies in complex with mucin deleted (DMuc) EBOV GP (Makona) and BDBV GPDMuc (Fig. 193 
2A-B, Fig. S2, Table S2). Antibodies exhibited a range of angles-of-approach to GP, from obtuse, 194 
such as EBOV-437, to nearly parallel to the viral surface, like EBOV-237 (Fig. 2C). Additionally, 195 
the antibodies are spaced across the surface of GP inversely related to their angle-of-approach 196 
(Fig. 2C).  197 
Resolutions achieved for glycan cap antibody cryo-EM structures ranged from 3.3 to 4.4 198 
Å for six of our complexes (Table S2, Fig. S2A-F); however, preferred orientation, sub-199 
stoichiometric Fab binding and trimer instability resulted in limited resolution for BDBV-329 and 200 
EBOV-237 bound structures (Fig. S2G-H). We did, however, model BDBV-329 where 201 
resolutions ranged from 4 to 5 Å at the antibody binding interface (Fig. S2G). The local resolutions 202 
for the EBOV-237 structure were particularly poor, and we therefore chose only to dock a 203 
homology model for interpretation (Fig. S2H). Most of our structures were determined in complex 204 
with EBOV-515 in order to assist with angular sampling and alignment, but we chose not to model 205 
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EBOV-515 and removed this density from our figures for clarity and to focus on glycan cap 206 
antibodies (Fig. 3A-B).  207 
All glycan cap antibodies make contacts exclusively within GP1 and are heavily biased 208 
toward HC contacts (Fig. 3, Table S3, Fig. S3). Antibody contacts are focused on the b17 strand 209 
of GP1 from residues 268-280 with a majority of contacts centered around W275 (Fig. 3, Table 210 
S3), which when mutated to alanine abrogates binding (Table 1, Fig. S1B). Additionally, most 211 
glycan cap antibodies make some contact with the inner head domain (Fig. 3, Table S3, Fig. S3). 212 
These contacts are characterized by hydrogen bonding along the length of b17 with either short 213 
CDRH2 loops for EBOV-293 (Fig. 3A-B, Fig. S3A) and BDBV-43 (Fig. 3C-D, Fig. S3B) or 214 
extended, long (³ 21 amino acids) CDRH3 loops for EBOV-437 (Fig. 4F, Fig. S5C), BDBV-289 215 
(Fig. 3G-H, Fig. S3D), EBOV-442 (Fig. 3I, Fig. S3E) and EBOV-296 (Fig. 3J-K, Fig. S3F), 216 
very similar to EBOV-548 as we previously reported (Gilchuk et al., 2020). Outside of the 217 
hydrogen bonding that occurs along b17, several glycan cap antibodies make additional stabilizing 218 
bonds, including hydrogen bonds, salt bridges, carbon-pi and pi-pi bonds with other portions of 219 
GP1 (Fig. 3). Methionine-aromatic interactions also appear in several of the glycan cap antibodies, 220 
particularly with W275 in GP1 (Fig. 3D, H, J). These types of interactions are thought to provide 221 
additional stability compared to purely hydrophobic interactions, can act at long distances (~5-6 222 
Å) and are thought to be less sensitive to changes in the local environment (Valley et al., 2012) , 223 
which may help contribute to increased breadth. 224 
The CDRH3 loops of the glycan cap antibodies generally adopt an extended b-hairpin 225 
motif with either partial or full b-strand secondary structure (Fig. 4A). These loops also pair with 226 
b17 in GP1 to form an extended b-sheet and displace the b18-b18¢ hairpin by mimicking its 227 
structure, as was observed in our previous structure of EBOV-548 (Fig. 4B). BDBV-43 and 228 
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EBOV-293 alternatively use shorter CDRH2 loops to pair with b17 (Fig. 4A-B). Conversely, 13C6 229 
has a much shorter CDRH3 loop and does not make full contact with b17 (Fig. 4B), possibly 230 
explaining its lack of synergy with base antibodies (Fig. 1A). EBOV-237 and BDBV-329 are 231 
unique among the antibodies we examined here owing to very long CDRH3 loops at 25 or 33 232 
amino acids, respectively.  233 
We also determined the unliganded crystal structure of BDBV-289 Fab to 3.0 Å resolution 234 
to compare the confirmations of the CDR loops prior to GP engagement (Fig. 4C, Table S4). The 235 
structure of the unliganded BDBV-289 Fab is very similar to BDBV-289 Fab bound to EBOV 236 
GPDMuc, with an RMSD of 1.6 Å for the Fv portions of the HC and LC (Fig. 4C). There is a 237 
slight shift of the CDRL3 to accommodate the a2-b17 loop in the glycan cap, and a larger shift of 238 
CDRH3 (Fig. 4C). In the GP-bound structure, the CDRH3 loop moves toward GP by an average 239 
distance of ~3.3 Å (Fig. 4C). In the crystal structure, this movement is blocked by a crystal lattice 240 
interaction, but this difference may indicate flexibility in the tip of this loop. 241 
 242 
The b18-b18¢ hairpin anchors the mucin-like domains and shields a hydrophobic patch in the 243 
glycan cap 244 
The b18-b18¢ region of the glycan cap forms a b-hairpin that anchors the MLD, forming 245 
an extended beta sheet with the underlying core of GP1 (Fig. 5A) (Zhao et al., 2016). Due to the 246 
recurrence of the b18-b18¢ hairpin epitope within the glycan cap and its role in anchoring down 247 
MLD, we have named this portion of the glycan cap the “MLD-anchor” (Fig. 5A). Upon binding 248 
of glycan cap antibody, the MLD-anchor is displaced, revealing a patch of hydrophobic residues, 249 
which we refer to as the “MLD-cradle” (Fig. 5B).  250 
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The MLD-anchor contains complementary hydrophobic residues along the b18¢ strand that 251 
are buried by the MLD-cradle (Fig. 5C). Through molecular mimicry, the CDRH3 or CDRH2 252 
loops of each of the neutralizing glycan cap antibodies characterized in this study bury analogous 253 
hydrophobic residues in the cradle, displacing the anchor (Fig. 5C). Our structures of EBOV-548 254 
(Gilchuk et al., 2020) Fab and BDBV-289 Fab bound to GP indicate that although binding 255 
abrogates attachment of the MLD-anchor, the b17-b18 loop most likely remains tethered to the 256 
base of the IFL via W291GP1 to N512GP2. However, glycan cap binding may remove some restraint 257 
on the b17-b18 loop, allowing increased binding by GP base-directed antibodies. 258 
The sequence of the N-terminal portion of the MLD-anchor (b18), the MLD-cradle and the 259 
b17-b18 loops are relatively conserved throughout all ebolaviruses, however, the surrounding 260 
regions in the glycan cap are not (Fig. 5D-E, Fig. S4). The glycan cap antibody contacts described 261 
here are focused toward b17 but other contacts outside this region are also observed (Fig. S4, 262 
Table S3). While each glycan cap antibody makes contacts outside the most conserved regions, 263 
there is less reliance on these regions for contact in the more cross-reactive antibodies (Fig. S4).  264 
 265 
Germline analysis and conservation of features within glycan cap antibody paratopes 266 
 The glycan cap antibodies described here share several common features, including a 267 
majority (5 out of 9) deriving from the IGHV1-69 germline gene segment (Table S1). Frequent 268 
use of the IGHV1-69 gene is common in the antibody repertoires of those infected by influenza 269 
virus (Lang et al., 2017), HCV (Chan et al., 2001), HIV-1 (Huang et al., 2004), and other pathogens 270 
(Chen et al., 2019). The IGHV1-69 gene is thought to be superior for viral neutralization at certain 271 
epitopes due to the presence of key germline encoded hydrophobic residues, especially in the 272 
CDRH2, as well as for breadth due to a large repertoire of allelic and copy number variations 273 
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(Chen et al., 2019). Despite a wide range of donors, we found these characteristics present in the 274 
ebolavirus antibodies described here (Table S1, Fig. S5). 275 
Eight of the nine of the human antibodies described here use IGHV1-69 and/or IGHJ6 276 
genes to form their HCs (Table S1, Fig. S5), the exception being EBOV-237. The use of IGHV1-277 
69 imparts a germline-encoded CDRH2 with several hydrophobic residues, which is used by 278 
BDBV-43 and EBOV-293 to bind to the MLD-cradle (Fig. 5C). In these cases, the CDRH3 loops 279 
are shorter (Fig. S5). For the rest of the glycan cap antibodies, usage of IGHJ6 appears to be key, 280 
due to the presence of a patch of tyrosine residues in the germline gene which sit on the C-terminal 281 
end of the CDRH3 (Fig. S5). Overall, somatic hypermutation (SHM) was generally high 282 
throughout all glycan cap mAbs studied here, with an average of ~11% or ~6% amino change from 283 
germline for the VH or VL regions, respectively (Table S1). 284 
Despite varying CDRH3 length, the tip of the CDRH3 hairpin contains a highly conserved 285 
glycine surrounded by hydrophobic residues and a C-terminal tyrosine motif (Fig. 5F). This 286 
glycine and hydrophobic tip help to insert the CDRH3 loop into the MLD-cradle (Fig. 5A-C) and 287 
assists in formation of the hairpin structure necessary for proper binding. The C-terminal tyrosine 288 
motif stabilizes longer CDRH3 loops within the core of the paratope and provides additional, non-289 
specific hydrophobic contacts within the core of the epitope.  290 
 291 
Glycan cap antibodies inhibit cleavage  292 
The underlying molecular mechanism for how an antibody neutralizes is related to its 293 
ability to inhibit viral infection, which can be achieved by diverse mechanisms including cleavage 294 
inhibition. To determine the ability of the antibodies used in this study to inhibit cleavage, we 295 
performed a cleavage-blocking assay as previously described (Gilchuk et al., 2018) (Fig. 6A). 296 
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Jurkat cells stably transduced with EBOV GP (Jurkat-EBOV GP) were pre-incubated with 297 
individual antibodies followed by treatment with thermolysin to mimic cathepsin cleavage to yield 298 
membrane-displayed GPCL (Jurkat-EBOV GPCL). The exposure of the receptor binding site (RBS) 299 
on GPCL was measured by the level of binding of fluorescently labeled RBS-specific mAb MR78 300 
that does not bind uncleaved EBOV GP (Flyak et al., 2015) The epitope of glycan cap antibodies 301 
is being removed by cleavage, and in a separate assay we confirmed that none of tested antibodies, 302 
except EBOV-442, compete with MR78 on Jurkat-EBOV GPCL (Fig. S6). EBOV-442 partially 303 
competed with MR78 (Fig. S6), suggesting incomplete removal of its epitope by thermolysin that 304 
may have a minor effect on quantification of cleavage inhibition by this antibody. All EBOV GP-305 
reactive glycan cap antibodies revealed dose-dependent cleavage inhibition and most of them fully 306 
blocked cleavage at the highest tested concentration of 60 μg/mL (Fig. 6A). Base antibody 2G4 307 
and control antibody 2D22 did not inhibit cleavage. Although the glycan cap antibodies in this 308 
study do not interact directly with the cathepsin cleavage loop, the disruption or dislocation of the 309 
MLD may provide an obstacle for the recognition or cleavage activity by enzymes (Fig. 6B).  310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
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Discussion 320 
Our previous structure of the EBOV-548/EBOV GP complex first revealed the glycan cap 321 
binding site containing the b18-b18¢ hairpin (Gilchuk et al., 2020); however, the extensive 322 
structural evidence we provide here more completely describes this epitope, which we coin the 323 
MLD-anchor and cradle. The displacement of the MLD-anchor suggests that it is bound 324 
transiently, similar to the b17-b18 loop (West et al., 2019). Anecdotally, we and others have often 325 
noticed that the glycan cap is not well resolved in negative stain and cryo-EM structures of GP 326 
that lack coordinating glycan cap antibodies, suggesting this entire domain may be loosely attached 327 
to GP. This transient structural feature may aid in removal of the glycan cap upon cleavage for 328 
exposure of the NPC1 binding site. The MLD-anchor makes very limited contact with the 329 
underlying hydrophobic cradle, essentially mediated by a single b-strand. These characteristics 330 
have been observed for other antibodies that bind with hydrophobic, hairpin CDR loops, 331 
suggesting a conserved mechanism for neutralization that extends to other viruses (Lee et al., 2017; 332 
Pancera et al., 2010; Yuan et al., 2019). 333 
Some of the antibodies in this study shared structural features that correlated with shared 334 
antibody germline gene usage, despite having been isolated from separate donors. For example, 335 
BDBV-43 and EBOV-293 are both encoded by the IGHV1-69*09 gene allele, which is known to 336 
contain a germline-encoded hydrophobic CDRH2. These antibodies, accordingly, use their 337 
CDRH2 loops to access b17. However, several other antibodies in this study also use the IGHV1-338 
69 gene, but alternatively use longer CDRH3 loops to access b17. BDBV-43 and EBOV-293 also 339 
share almost identical LC usage (IGKV3-15*01 and 3-20*01 for VL genes and IGKJ5*01 for JL 340 
genes, respectively). Their structures are nearly identical as well, which indicates that LC pairing 341 
may influence access to b17 by IGHV1-69 gene-encoded CDRH2 loops. However, this barrier can 342 
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be overcome through a larger number of non-templated (N) nucleotide additions within the 343 
CDRH3 when using alternative LC pairing. These observations may indicate that germline 344 
targeting vaccines could be an effective strategy for eliciting similar antibodies for EBOV in 345 
healthy individuals, similar to what has been shown in HIV-1 vaccine studies (Steichen et al., 346 
2016; Steichen et al., 2019).  347 
The glycan cap antibodies described here generally have high levels of SHM, with EBOV-348 
293 containing 24 mutations from the inferred germline gene in its heavy chain (Table S1). This 349 
count also does not consider potential somatic mutations in the long CDRH3 loops, whose 350 
germline origins cannot be predicted but likely arise from large numbers of N-additions during the 351 
original V-D-J recombination event. How glycan cap antibody SHM compares to mutation 352 
frequency in antibodies directed toward other epitopes is not well explored, but the amount of 353 
SHM we observe for these neutralizing glycan cap mAbs is higher than is generally reported in 354 
EBOV survivor repertoires (Davis et al., 2019). Glycan cap antibodies are now known to form a 355 
large portion of the adaptive response to natural infection (Bornholdt et al., 2016b; Flyak et al., 356 
2016; Wec et al., 2017). Several of these antibodies can potently neutralize, however, they are 357 
often mono-specific. It is unclear how the smaller subset of rarer, broadly neutralizing glycan cap 358 
antibodies develops. Our observations indicate that they may require higher levels of SHM 359 
combined with structural adaptations in order to reach cryptic epitopes shielded by the MLD, the 360 
MLD-anchor and glycans. 361 
The mechanism of viral neutralization by glycan cap antibodies is unclear. Potentially, 362 
these antibodies could act indirectly by preventing access to a cleavage loop that is necessary to 363 
cleave during viral entry (Bornholdt et al., 2016a) (Fig. 6B, part I). The MLDs are large, 364 
accounting for over half of the mass of GP, unstructured and highly glycosylated. While the MLDs 365 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted October 14, 2020. . https://doi.org/10.1101/2020.10.14.340026doi: bioRxiv preprint 
 17 
on ebolaviruses are known to sit atop the GP, those on marburgviruses are thought to drape over 366 
the sides (Hashiguchi et al., 2015). This difference may occur because marburgviruses lack the 367 
structured glycan cap that is found in ebolaviruses (King et al., 2018). Consequently, the NPC1 368 
receptor binding site is fully exposed on full-length GP in marburgviruses (Flyak et al., 2015), 369 
while it is hidden under the glycan cap and MLD on ebolaviruses. Therefore, the MLD-anchor 370 
appears to pin the MLD down to the top of ebolavirus GPs, keeping them above the GP and out of 371 
the way of the cleavage loop. Displacing the MLD-anchor may displace the MLDs themselves 372 
while retaining covalent attachment of these large domains to GP (Fig. 6B, part II). Within the 373 
dense environment of the ebolavirus surface, in which many GP spikes are known to crowd 374 
together in close proximity (Tran et al., 2014), this displacement may cause the MLD to drape over 375 
the cathepsin cleavage loops, thus blocking access by enzymes.  376 
Overall, our data collectively provide the molecular basis for breadth of reactivity and virus 377 
neutralization by potent glycan cap antibodies and suggest a rational strategy for the design of 378 
broad therapeutic antibody cocktails.  379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
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Figure Legends 435 
 436 
Figure 1. Glycan cap antibody synergy and GP destabilization. A) Jurkat cell-surface 437 
displayed EBOV GP binding was assessed using fluorescently labeled EBOV-515 or EBOV-520 438 
after prior incubation of cells with individual unlabeled glycan cap antibodies. The blue dotted 439 
line represents basal binding of base antibodies without glycan cap antibodies. The orange dotted 440 
line represents maximal binding of base antibodies to cleaved GP. Data shown as mean ± SD of 441 
technical triplicates B) Negative stain 2D-class averages of GP complexes bound to glycan cap 442 
antibodies and EBOV-515 demonstrating examples of intact, trimeric complexes (left) and 443 
monomeric complexes (right). C) Correlation analysis of antibody synergy and GP 444 
destabilization by glycan cap antibodies.  445 
 446 
Figure 2. Neutralizing and synergistic glycan cap antibodies bind GP across a wide range 447 
of orientations. A) Low-pass filtered glycan cap Fabs from cryo-EM structures solved in this 448 
study, as well as elsewhere, bound to EBOV GPDMuc are overlaid to compare binding epitope 449 
and angle-of-approach. B) Surface representations of cryo-EM structures solved in this study 450 
with a fitted ribbon model protomer. Shown are side (left) or top (right) views with respect to the 451 
viral membrane. Fab HC is colored in dark tones and LC in light tones. Co-binding antibodies 452 
were removed from reconstructions for clarity. C) Relationship between antibody angle-of-453 
approach and Fab spacing. An angle-of-approach of zero degrees is considered parallel and 90° 454 
is considered perpendicular to the viral surface. An angle-of-approach greater than 90° indicates 455 
antibodies that bind inward toward the head domain while less than 0° indicates antibodies that 456 
bind upward from the viral membrane. Fab spacing is determined by averaging the distance from 457 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted October 14, 2020. . https://doi.org/10.1101/2020.10.14.340026doi: bioRxiv preprint 
 21 
the same point on modeled Fab hinge terminal residues in the HC and LC. Antibodies are labeled 458 
as in part A. See also Figure S2 and Figure S4. 459 
 460 
Figure 3. Structural details of glycan cap antibody binding to GP. Single protomers from 461 
structural models are shown with close-up views of interacting regions. HCs are rendered in 462 
darker colors and LCs in lighter colors, with GP1 colored white. Important residues that 463 
coordinate interaction and binding are highlighted. A) Key residues in the EBOV-293 CDRH2 464 
hydrogen bond along the length of b17 with an additional potential salt bridge between E65H2 465 
and K276GP1. B) The EBOV-293 CDRH2 and H3 make additional contacts, including at W275, 466 
and the LC forms potential hydrogen bonds between a2 and b17. C) Similar to EBOV-293, the 467 
BDBV-43 CDRH2 loop binds along b17. D) The BDBV-43 CDRH2 makes additional contacts 468 
at W275 and also contacts the loop between a2 and b17 via its LC. E) The EBOV-43 CDRH3 469 
loop displaces the loop between a2 and b17, shifting N268 by ~8 Å (apo-GP in white and 470 
BDBV-43 bound GP in grey). F) EBOV-437 makes contact with GP exclusively with its HC, 471 
hydrogen bonding along b17 with its CDRH3 and contacting the head domain in several places. 472 
G) BDBV-289 makes extensive hydrogen bonds with its CDRH3 along b17. H) The BDBV-289 473 
CDRH3 contacts W275 via methionine-aromatic and pi-pi interactions. Additional contacts are 474 
made with the head domain of GP via hydrophobic interactions with the CDRH2. I) BDBV-442 475 
makes contact with GP exclusively with its HC. The CDRH3 makes hydrogen bonds along b17, 476 
with W275 with hydrophobic interactions and along the loop between a2 and b17. J) EBOV-296 477 
binds to GP along b17, contacting W275 via methionine-aromatic and pi-pi interactions. The LC 478 
makes further contact to the head domain of GP with several potential salt bridges. K) The 479 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted October 14, 2020. . https://doi.org/10.1101/2020.10.14.340026doi: bioRxiv preprint 
 22 
EBOV-296 LC also makes contact to the loop between a2 and b17. See also Figure S3 and 480 
Figure S4, Table S2 and Table S3. 481 
 482 
Figure 4. Glycan cap antibody paratopes feature long CDRH3 or short CDRH2 loops with 483 
beta-hairpin structures that mimic and displace the b18- b18¢ region in the glycan cap. A) 484 
Ribbon models of the glycan cap antibody Fv domains with CDR loops highlighted. The HC is 485 
in dark gray (right) and the LC is in light grey (left). B) Structures highlighting the interaction of 486 
each of the glycan cap antibodies with the b17 strand, which forms the basis of an extended beta 487 
sheet in the glycan cap with the b17- b18 loop and b18- b18¢ hairpin motif (shown on the left). 488 
C) Crystal structure of BDBV-289 Fab. Shown on the right is comparison of the apo- and GP-489 
bound forms of BDBV-289. *From a previous study; ☨shown as an initial homology model. 490 
EBOV-548 (PDB 6UYE) and 13C6 (PDB 5KEL) are included in this figure for comparison. See 491 
also Figure S5, Table S2 and Table S4. 492 
 493 
Figure 5. Glycan cap antibodies target a conserved, hydrophobic cradle that anchors the 494 
mucin-like domains to GP1. A) Hydrophobicity surface rendering of apo-EBOV GP protomer 495 
(PDB 5JQ3) with the MLD-anchor (b18- b18¢) highlighted in red. Using the Kyte and Doolittle 496 
scale (Kyte and Doolittle, 1982), hydrophobic residues are colored orange with hydrophilic ones 497 
in blue. B) Upon glycan cap mAb binding, the MLD-anchor is displaced, exposing a 498 
hydrophobic pocket we term the “MLD-cradle”. The cradle lies within a groove formed by a2 499 
and b17, directly above the 310 pocket. Key residues of the cradle are indicated. The MLD-cradle 500 
is composed of residues from a2 and b17 as well as some additional residues that lie deeper in 501 
the core of GP1, including I218, F248, F252, L253, L256, I260, G264, L273, I274, W275, V277 502 
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and L244. The cradle is segmented in the middle by W275, which may explain this residue’s 503 
pivotal role in the binding of many glycan cap antibodies to GP. C) Interaction of glycan cap 504 
mAb HC loops with the MLD-cradle (from the rectangle in panel B). Key hydrophobic residues 505 
from antibody paratopes are indicated. D) Sequence alignment of the MLD-anchor and cradle 506 
epitope for the five main ebolaviruses (EBOV Q05320, BDBV B8XCN0, SUDV Q66814, 507 
TAFV Q66810 and RESTV Q66799) with topology indicated below. Residues highlighted in 508 
orange are key hydrophobic residues that form the cradle, those in green form the base of the 509 
b17- b18 loop that interact with the base of the fusion loop, and those in red are key residues 510 
from b18 that interact with the cradle in apo-GP. Those marked with a * are common escape 511 
mutants for this epitope. E) Glycan cap antibody footprints highlighted on the structure of apo-512 
GP colored to reflect conservation, with dark purple indicating complete lack of conservation 513 
and white indicating complete conservation. F) Shown is a sequence alignment of the CDRH3 514 
region from each of the glycan cap antibodies analyzed in this study, with darker pink indicating 515 
complete conservation and light pink indicating complete lack of conservation. The beta-turn-516 
beta structure common to these paratopes is indicated above. Key sequences that are similar 517 
among these antibodies are boxed in black with “Y” stretches from IGHJ6 gene usage underlined 518 
in purple. See also Figure S5. 519 
 520 
Figure 6. Cleavage inhibition by glycan cap antibodies. A) Jurkat-EBOV GP was incubated 521 
with various concentrations of antibodies, treated with thermolysin, and then assayed using flow 522 
cytometry for exposure of the receptor binding site (RBS) as measured by binding of a 523 
fluorescently labeled MR78 antibody that recognizes the RBS. Determined IC50 and IC90 values 524 
(left) and dose-dependent inhibition curves (right) are shown. Dotted line indicates % RBS 525 
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exposure in the presence of 2D22 control. BDBV-329 was excluded because it does not bind to 526 
EBOV GP, and BDBV-43 was not tested due to poor recombinant expression. B) Proposed 527 
model of the GP inhibition by glycan cap antibodies: I. Enzyme cleavage of a loop draped over 528 
the outside of GP (magenta) is thought to release the glycan cap and attached MLD. II. Glycan 529 
cap antibodies that bind to the MLD-cradle displace the MLD-anchor and thus the MLDs 530 
themselves, potentially shifting their position and sterically blocking access to the cleavage loop 531 
by enzymes, especially on a GP-dense viral surface. See also Figure S6. 532 
 533 
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 549 
Table 1. Summary of binding and functional activities of characterized antibodies.  550 
Characteristics for previously described antibodies were included for comparative purposes. 551 
*Determined in this study; ** prophylaxis efficacy; ***incomplete neutralization at highest tested 552 
Ab concentration (0.2 mg/mL); “>” indicates activity was not detected at highest tested Ab 553 
concentration; ND – not determined. See also Figure S1 and Table S1. 554 
 555 
 556 
Antibody 
GP binding by ELISA, EC50 
(ng/mL) 
Virus neutralization, IC50 
(ng/mL)  Site 
on 
GP 
GP 
mutations  
IgG therapy 
in mice 
(EBOV), % 
survival 
Antibody 
source EBOV 
GP  
BDBV 
GP  
SUDV 
GP  
EBOV 
sGP* EBOV  BDBV  SUDV  
EBOV-293  49 198 91 3 1,672 1,892 10,456 GC T240A, W275A 100* This study 
EBOV-296 39 78 514 4 5,758 534 39,217 GC W275A 20* This study 
BDBV-329 > 135 > 
21 
(BDBV 
sGP) 
> 770 > GC ND ND Flyak et al. 2016 
BDBV-289 29 20 103 1 602 32 > GC W275A, Y241A 80 
Flyak et al. 
2016 
BDBV-43 22 29 21 
18 
(BDBV 
sGP) 
7,248 139 318 GC L273P 20 Flyak et al. 2016 
EBOV-237 25 3,367 > 162 780 ND ND GC 
I260R, 
N278A, 
P279A, 
S322G 
80-90** Williamson et al. 2019 
EBOV-437 3 11 4 1 8,660*** > > GC W275A ND Gilchuk et al. 2018 
EBOV-442 1 3 6 1 467 1,489 <75%*** GC W275A, L273P 80 
Gilchuk et 
al. 2018 
EBOV-548 6 7 132 1 1,601 2,262 <12%*** GC 
T240A, 
R266A, 
T269A, 
T270A, 
I274A, 
W275 
40 Gilchuk et al. 2020 
13C6 20 > > 2 > > > GC 
T270A, 
K272A, 
T240N 
100 Wilson et al. 2000 
2G4 203 > > > 139 > > Base 
C511A, 
G553A, 
N550A, 
D552A, 
C556A, 
Q508R 
60 Qiu et al. 2012 
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STAR Methods 557 
 558 
RESOURCE AVAILABILITY 559 
Lead contact 560 
Further information regarding requests for resources and reagents should be directed to and 561 
will be fulfilled by the Lead Contact, Andrew Ward (andrew@scripps.edu). 562 
 563 
Materials availability 564 
 Plasmids generated in this study are available upon request by the Lead Contact. 565 
 566 
Data and code availability 567 
The cryo-EM maps and structural coordinates generated during this study are available at 568 
the Electron Microscopy Data Bank (www.ebi.ac.uk/pdbe/emdb) and the Worldwide Protein Data 569 
Bank (www.pdb.org). The accession codes for the following cryo-EM maps reported in this paper 570 
are: EMD-22839 (EBOV GPDMuc:BDBV289 Fab), EMD-22841 (BDBV GPDMuc:BDBV43 Fab 571 
and ADI-15878 Fab), EMD-22853 (EBOV GPDMuc:EBOV-437 Fab and EBOV-515 Fab), EMD-572 
22848 (EBOV GPDMuc:EBOV-442 Fab and EBOV-515 Fab), EMD-22842 (EBOV 573 
GPDMuc:EBOV-293 Fab and EBOV-515 Fab), EMD-22847 (EBOV GPDMuc:EBOV-296 Fab 574 
and EBOV-515 Fab), EMD-22851 (EBOV GPDMuc:BDBV-329 Fab and EBOV-515 Fab) and 575 
EMD-22852 (EBOV GPDMuc:EBOV-237 Fab and EBOV-515 Fab). The accession codes for 576 
PDB files are: 7KEJ (EBOV GPDMuc:BDBV-289 Fab), 7KEW (BDBV GPDMuc:BDBV-43 577 
Fab), 7KFH (EBOV  GPDMuc:EBOV-437 Fab), 7KFB (EBOV GPDMuc:EBOV-442 Fab), 7KEX 578 
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(EBOV GPDMuc:EBOV-293 Fab), 7KF9 (EBOV GPDMuc:EBOV-296 Fab), 7KFE (EBOV 579 
GPDMuc:BDBV-329 Fab) and 7KFG (unliganded BDBV289 Fab). 580 
 581 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 582 
Human samples 583 
Human PBMCs were obtained from a survivor of the 2014 EVD epidemic who acquired 584 
the infection in the Democratic Republic of Congo and was treated in the Nebraska Medical Center 585 
in the United States. A male human survivor was age 57 when PBMCs were collected. PBMCs 586 
were collected after the illness had resolved, following written informed consent. The studies were 587 
approved by the Institutional Review Board of Vanderbilt University Medical Center. 588 
 589 
Cell lines 590 
Suspension adapted HEK293F cells were obtained from ThermoFisher Scientific and 591 
cultured in serum-free FreeStyle medium. Cells were maintained in shaking incubators at 100% 592 
humidity, 37°C and 8% CO2. Expi293F cells (ThermoFisher Scientific) were maintained at 37 °C 593 
in 8% CO2 in Expi293F Expression Medium (ThermoFisher Scientific). ExpiCHO cells 594 
(ThermoFisher Scientific) were maintained at 37°C in 8% CO2 in ExpiCHO Expression Medium 595 
(ThermoFisher Scientific). The Jurkat-EBOV GP (variant Makona) cell line stably transduced to 596 
display respective GP on the surface (Davis et al., 2019) was a kind gift from Carl Davis (Emory 597 
University, Atlanta, GA). Jurkat-EBOV GP cells were maintained at 37°C in 8% CO2 in RPMI-598 
1640 medium (Gibco) supplemented with 10% fetal heat-inactivated fetal bovine serum (FBS). 599 
Mycoplasma testing of Expi293F and ExpiCHO cultures was performed on a monthly basis using 600 
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a PCR-based mycoplasma detection kit (ATCC). Cell lines were not authenticated following 601 
purchase.  602 
 603 
Viruses 604 
Mouse-adapted EBOV Mayinga (EBOV-MA, GenBank: AF49101) virus was described 605 
previously (Bray et al., 1998). 606 
 607 
Mouse models 608 
Seven- to eight-week old female BALB/c mice were obtained from the Jackson Laboratory. 609 
Mice were housed in microisolator cages and provided food and water ad libitum. Challenge 610 
studies were conducted under maximum containment in an animal biosafety level 4 (ABSL-4) 611 
facility of the Galveston National Laboratory, UTMB. The animal protocols for testing of mAbs 612 
in mice were approved by the Institutional Animal Care and Use Committee (IACUC) of the 613 
University of Texas Medical Branch in compliance with the Animal Welfare Act and other 614 
applicable federal statutes and regulations relating to animals and experiments involving animals. 615 
 616 
METHOD DETAILS 617 
Isolation of mAbs EBOV-293 and EBOV-296  618 
Hybridoma cell lines secreting human mAbs were generated as described previously 619 
(Flyak et al., 2018). In brief, previously cryopreserved samples were transformed with Epstein-620 
Barr virus, CpG and additional supplements. After 7 days, cells from each well of the 384-well 621 
culture plates were expanded into four 96-well culture plates using cell culture medium 622 
containing irradiated heterologous human PBMCs (recovered from blood unit leukofiltration 623 
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filters, Nashville Red Cross) and incubated for an additional four days. Plates were screened for 624 
EBOV GP antigen-specific antibody-secreting cell lines using enzyme-linked immunosorbent 625 
assays (ELISAs). Cells from wells with supernatants reacting with antigen in an ELISA were 626 
fused with HMMA2.5 myeloma cells using an established electrofusion technique (Yu et al., 627 
2008). Antibody heavy- and light-chain variable region genes were sequenced from hybridoma 628 
lines that had been cloned biologically by single-cell flow cytometric sorting. Briefly, total RNA 629 
was extracted using the RNeasy Mini kit (QIAGEN) and reverse-transcriptase PCR (RT-PCR) 630 
amplification of the antibody gene cDNAs was performed using the PrimeScript One Step RT-631 
PCR kit (CLONTECH) according to the manufacturer’s protocols with gene-specific primers 632 
(Thornburg et al., 2016). The thermal cycling conditions were as follows: 50°C for 30 min, 94°C 633 
for 2 min, 40 cycles of (94°C for 30 s, 58°C for 30 s and 72°C for 1 min). PCR products were 634 
purified using Agencourt AMPure XP magnetic beads (Beckman Coulter) and sequenced 635 
directly using an ABI3700 automated DNA sequencer. The identities of gene segments and 636 
mutations from germlines were determined by alignment using the ImMunoGeneTics database 637 
(Giudicelli and Lefranc, 2011). 638 
 639 
Synergistic binding to cell-surface-displayed GP 640 
The assay was performed as described previously (Gilchuk et al., 2018). Briefly, Jurkat-641 
EBOV GP cells were pre-incubated at 4°C for 30 min with individual unlabeled glycan cap-642 
specific mAbs at a saturating for GP binding concentration (20 μg/mL) in PBS containing 2% 643 
FBS and 2 mM EDTA, and then Alexa Fluor 647-labeled mAbs EBOV-515 or EBOV-520 were 644 
added to a total concentration of labeled mAbs of 10 μg/mL. Cells were incubated at 4°C for 645 
additional 2 h, then washed and antibody binding was analyzed by flow cytometry using an iQue 646 
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Screener Plus flow cytometer (Intellicyt). Controls included binding of labeled mAb to mock-647 
transduced Jurkat cells (background), binding of labeled mAb alone to intact Jurkat-EBOV GP (a 648 
baseline level of binding to calculate fold change in a presence of glycan mAb), and binding of 649 
labeled mAb alone to cleaved Jurkat-EBOV-GP (maximal saturating binding signal). Results are 650 
expressed as fold-increase in median fluorescence intensity (MFI) of labeled mAb binding in the 651 
presence of the tested unlabeled mAb minus background signal from mock control.  652 
 653 
ELISA binding assays 654 
To assess mAb binding at different pH, wells of 96-well microtiter plates were coated 655 
with purified, recombinant EBOV, BDBV or SUDV GPDTM ectodomains or EBOV sGP at 4˚C 656 
overnight. Plates were blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS 657 
containing 0.05% Tween-20 (DPBS-T) for 1 h. Purified mAbs were diluted serially in DPBS-T 658 
(pH 7.4), or DPBS-T that was adjusted to pH 5.5 or 4.5 with hydrochloric acid, added to the 659 
wells and incubated for 1 h at ambient temperature. The bound antibodies were detected using 660 
goat anti-human IgG conjugated with horseradish peroxidase (Southern Biotech) diluted in 661 
blocking buffer and TMB substrate (ThermoFisher Scientific). Color development was 662 
monitored, 1N hydrochloric acid was added to stop the reaction, and the absorbance was 663 
measured at 450 nm using a spectrophotometer (Biotek). 664 
 665 
Epitope mapping using an EBOV GP alanine-scan mutation library 666 
Epitope mapping was carried out as described previously (Gilchuk et al., 2018). 667 
Comprehensive alanine scanning (‘shotgun mutagenesis’) was carried out on an expression 668 
construct for EBOV GP (Yambuku-Mayinga variant) lacking the mucin-like domain (residues 669 
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311-461), mutagenizing GP residues 33-310 and 462-676 to create a library of clones, each 670 
representing an individual point mutant. Residues were changed to alanine (with alanine residues 671 
changed to serine). The resulting library, covering 492 of 493 (99.9%) of target residues, was 672 
arrayed into 384-well plates, one mutant per well, then transfected into HEK-293T cells and 673 
allowed to express for 22 hrs. Cells, unfixed or fixed in 4% paraformaldehyde, were incubated 674 
with primary antibody and then with an Alexa Fluor 488-conjugated secondary antibody (Jackson 675 
ImmunoResearch Laboratories). After washing, cellular fluorescence was detected using the 676 
Intellicyt flow cytometer. MAb reactivity against each mutant EBOV GP clone was calculated 677 
relative to wild-type EBOV GP reactivity by subtracting the signal from mock-transfected controls 678 
and normalizing to the signal from wild-type GP-transfected controls. Mutated residues within 679 
clones were identified as critical to the mAb epitope if they did not support reactivity of the test 680 
mAb but did support reactivity of other control EBOV mAbs. This counter-screen strategy 681 
facilitated the exclusion of GP mutants that were misfolded locally or that exhibited an expression 682 
defect. The detailed algorithms used to interpret shotgun mutagenesis data were described 683 
previously (Davidson and Doranz, 2014). 684 
 685 
Mouse challenge and protection studies 686 
Groups of 7-8-week-old female BALB/c mice (n = 5 per group) housed in microisolator 687 
cages were inoculated with 1,000 PFU of the EBOV-MA by the intraperitoneal (i.p.) route. Mice 688 
were treated i.p. with 100 μg (∼5 mg/kg) of individual mAb per mouse on 1 dpi. Human mAb 689 
2D22 (specific to an unrelated target, dengue virus) served as a negative control (Fibriansah and 690 
Lok, 2016). Mice were monitored twice daily from day 0 to 14 post infection for illness, 691 
survival, and weight loss, followed by once daily monitoring from 15 dpi to the end of the study 692 
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at 28 dpi. The extent of disease was scored using the following parameters: dyspnea (possible 693 
scores 0–5), recumbence (0–5), unresponsiveness (0–5), and bleeding/hemorrhage (0–5). 694 
Moribund mice were euthanized as per the IACUC-approved protocol. All mice were euthanized 695 
on day 28 after EBOV challenge. 696 
 697 
Cryo-EM trimer stability assay 698 
Complexes for trimer stability assays were derived from data collected for structural 699 
evaluation (see Cryo-EM sample preparation section below). Particle picks were completed using 700 
a difference of gaussian method with low thresholds in order to pick everything on the grids. 701 
Particles were separated into stacks for either intact particles or particles that were falling apart, 702 
which was judged by eye, and then counted to determine approximate percentage of glycan cap 703 
antibody-induced instability. We have previously determined that base binding antibodies alone 704 
do not induce trimer instability. 705 
 706 
Cell surface displayed GP mAb competition-binding 707 
Jurkat-EBOV GPCL cells were pre-incubated with a saturating concentration (typically 708 
20 μg/mL) of glycan cap mAbs at room temperature for 30 min, followed by addition of labeled 709 
antibody MR78 (Flyak et al., 2015; Hashiguchi et al., 2015) at 5 μg/mL and incubated for an 710 
additional 30 min. Antibody MR78 was labeled with Alexa Fluor 647 and added after the first 711 
mAb and without washing of cells to minimize a dissociation of the first mAb from cell surface 712 
GP during a prolonged incubation. Cells were washed, fixed with 4% paraformaldehyde, and cell 713 
staining was analyzed using an iQue Screener Plus flow cytometer flow cytometer. Background 714 
values were determined from binding of the second labeled mAbs to untransfected Jurkat. 715 
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Results are expressed as the percent of binding in the presence of glycan cap mAb relative to 716 
MR78 alone (maximal binding) minus background. The antibodies were considered competing if 717 
the presence of first antibody reduced the signal of the second antibody to less than 35% of its 718 
maximal binding or non-competing if the signal was greater than 86%. A level of 36–85% was 719 
considered partial competition. Thermolysin cleavage removes the epitope for most tested glycan 720 
cap antibodies that showed very low binding to Jurkat-EBOV GPCL (data not shown). This study 721 
served as an additional control to confirm that cleavage inhibition measured as percent of RBS 722 
exposure is not due to MR78 binding completion with residually bound glycan cap antibody on 723 
Jurkat-EBOV GPCL.    724 
 725 
Cell surface displayed GP cleavage inhibition 726 
Jurkat-EBOV GP cells were pre-incubated with serial dilutions of mAbs in PBS for 727 
20 min at room temperature, then incubated with thermolysin (Promega) for 20 min at 37°C. The 728 
reaction was stopped by addition of the incubation buffer containing DPBS, 2% heat inactivated 729 
FBS and 2 mM EDTA (pH 8.0). Washed cells were incubated with 5 μg/mL of fluorescently 730 
labeled RBS-specific mAb MR78 at 4°C for 60 min. Stained cells were washed, fixed, and 731 
analyzed by flow cytometry using iQue Screener Plus flow cytometer. Cells were gated for the 732 
viable population. Background staining was determined from binding of the labeled mAb MR78 733 
to Jurkat-EBOV GP (uncleaved) cells. Results are expressed as the percent of RBS exposure in 734 
the presence of tested mAb relative to labeled MR78 mAb-only control (maximal binding to 735 
Jurkat-EBOV GPCL) minus background. The GP base-directed antibody 2G4 (Qiu et al., 2011) 736 
and 2D22 served as negative controls. BDBV-329 was excluded because it does not bind to 737 
EBOV and BDBV-43 was excluded due to poor recombinant expression of the antibody.  738 
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 739 
Construct design, expression and protein purification 740 
EBOV GP (Makona) (residues 32-644, GenBank AKG65268.1) with an N-terminal tissue 741 
plasminogen activator (Homo sapiens) signal sequence was codon optimized for mammalian 742 
protein expression, synthesized and subcloned into the pPPI4 expression vector (GenScript). A C-743 
terminal enterokinase (Ek) cut site (DDDDK) was introduced after residue 628 followed by a short 744 
linker (AG) and two streptavidin tags (WSHPQFEK) separated by a GS-linker 745 
(GGGSGGGSGGGS). Residues 310-460 were removed to produce EBOV GPDMuc. BDBV GP 746 
(residues 1-643, GenBank ALT19772.1) with the GP-associated signal peptide, an Ek cut site after 747 
residue 643 followed by an AG-linker and the double streptavidin tag as described above was 748 
codon optimized for mammalian protein expression, synthesized and subcloned into pPPI4. 749 
Residues 313-470 were removed to produce BDBV GPDMuc. EBOV sGP (Mayinga) (residues 1-750 
314, GenBank AAD14584.1) with the sGP-associated signal peptide an enterokinase cut site after 751 
residue 314 followed by an AG-linker and a double streptavidin tag was codon optimized for 752 
mammalian protein expression, synthesized and subcloned into pPPI4.  753 
 All GPs were expressed and purified in transiently transfected HEK-293F cells at a density 754 
of 0.8-1.5 x 106 cells/mL using 750 µg of DNA and 2.25 mg of polyethylenimine “Max” (MW 755 
25,000, Polyscience, Inc.) mixed with 50 mL of Opti-MEM (ThermoFisher Scientific). Solutions 756 
were sterile filtered using 0.22 µm Steriflip disposable filters (Millipore) and allowed to incubate 757 
at room temperature for 30 min before being added to cultures. After 5 days of expression at 37°C 758 
and 8% CO2, cells were harvested by centrifugation (8,000 x g for 1hr at 4°C) and filtered to 759 
remove cellular debris. BioLock biotin blocking solution (IBA Lifesciences) was added to 760 
supernatant according to the manufacturer’s protocol before being loaded onto Strep-Tactin 761 
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Superflow Plus beads (Qiagen) that had been pre-equilibrated in 1X Strep Buffer (100 mM Tris, 762 
pH 8.0, 150 mM NaCl and 1mM EDTA). Beads were washed with 10 mL of 1X Strep Buffer and 763 
GPs were eluted by addition of 2.5 mM d-desthiobiotin added to 10 mL of 1X Strep Buffer. GPs 764 
were further purified by size exclusion chromatography (SEC) using an S200 increase (S200I, GE) 765 
column equilibrated in 1X TBS (150 mM NaCl, 20 mM Tris, pH 7.4).  766 
 For EBOV-237, BDBV-329, EBOV-442, EBOV-437 and 2D22 recombinant mAb 767 
production, cDNA encoding the genes of heavy and light chains were cloned into the pTwist CMV 768 
Betaglobin WPRE Neo vector encoding IgG1 or Fab- heavy chain (McLean et al., 2000), or 769 
monocistronic expression vector pTwist-mCis_G1 (Zost et al., 2020) and transformed into E. coli 770 
cells. mAb proteins were produced after transient transfection of ExpiCHO cells following the 771 
manufacturer’s protocol and were purified from filtered culture supernatants by fast protein liquid 772 
chromatography (FPLC) on an AKTA instrument using HiTrap MabSelect Sure column for IgG 773 
(GE Healthcare Life Sciences) or CaptureSelect™ IgG-CH1 column for Fab (ThermoFisher 774 
Scientific). Purified mAbs were buffer exchanged into PBS, filtered using sterile 0.45 μm pore 775 
size filter devices (Millipore), concentrated, and stored in aliquots at −80°C until use. 776 
For BDBV-289, BDBV-43, EBOV-293 and EBOV-296 antibody expression, sequences 777 
were optimized for mammalian expression, synthesized and subcloned into the expression vector 778 
AbVec containing the human IgG HC constant region or the human lambda or kappa LC constant 779 
region (GenScript). Fab was produced by the introduction of a stop codon after residue 226 in the 780 
HC hinge-region. ADI-15878 Fab and ADI-16061 Fab were used as a fiducials in this study and 781 
were produced as previously described (Murin et al., 2018). IgGs and Fab were transiently 782 
transfected as described above for GPs, except that 500 µg of HC DNA and 250 µg of LC DNA 783 
was mixed to encourage HC/LC pairing and the avoidance of LC dimers. For BDBV-289 and 784 
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BDBV-43 Fab, cell supernatants were loaded onto 5 mL Lambda (BDBV-289) or Kappa (BDBV-785 
43) Select columns (GE) that had been equilibrated in 1X phosphate buffered saline (PBS, 786 
QualityBiological) followed by elution with 0.1 M glycine, pH 3.0. Fab were subsequently buffer 787 
exchanged into 20 mM sodium acetate (NaOAc), pH 5.6 by dialysis and loaded onto a MonoS 788 
column (GE). Fab were then eluted with a gradient of 1M KCl. For EBOV-437, EBOV-442, 789 
EBOV-293 and EBOV-296 Fab, cell supernatants were loaded onto a 1 mL or 5 mL Capture Select 790 
column (ThermoFisher Scientific) and eluted with 0.1 M glycine, pH 3.0. Appropriate fractions 791 
were pooled and further purified by SEC using an S200I column equilibrated in 1X TBS buffer. 792 
For IgG, supernatants were loaded onto a HiTrap 5 mL mAb Select column (GE) that had been 793 
pre-equilibrated in 1X PBS followed by elution with 0.1 M glycine, pH 3.0 and neutralization with 794 
1M Tris, pH 8.5. Appropriate fractions were pooled and further purified by SEC using an S200I 795 
column that had been equilibrated with 1X TBS. 796 
 797 
Crystallization and Structure Determination of BDBV-289 Fab 798 
 Fabs produced for crystallographic studies were made in Expi-CHO cells per the 799 
manufacturer’s “max titer” protocol (GIBCO/ThermoFisher Scientific) and purified as described 800 
above. BDBV-289 Fab was screened for crystallization using the Joint Center for Structural 801 
Genomics (JCSG) Rigaku CrystalMation at The Scripps Research Institute against the JCSG 802 
Core Suites I-IV. Protein at 7.4 mg/mL was mixed 1:1 with precipitants and crystallized using 803 
the vapor diffusion method at both room temperature and 4°C. Crystals grew in 0.1M HEPES pH 804 
6.5 and 20% (w/v) polyethylene glycol 6000 at 4°C. Crystals were cryoprotected with well 805 
solution augmented with 30% ethylene glycol. Data were collected at Stanford Synchrotron 806 
Radiation Light Source beamline 12-2. Data were indexed, integrated and scaled using HKL-807 
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2000 (Otwinowski and Minor, 1997) to 3.0 Å (Table S2). Crystals belonged to the space group 808 
P61 with a single Fab in the asymmetric unit.  809 
 Data were phased using Phaser (McCoy et al., 2007) with molecular replacement by a 810 
homology model generated using Swiss Modeler (Biasini et al., 2014). A single Fab was placed 811 
in the asymmetric unit. This initial solution was rebuilt manually in Coot (Emsley et al., 2010), 812 
followed by multiple rounds of refinement in Phenex.refine (Adams et al., 2010) and model 813 
building with Coot. Translation/Libration/Screw (TLS) groups were introduced towards the end 814 
of refinement. Four TLS groups were set manually with one for each immunoglobulin domain. A 815 
large positive density seen in the difference map was modeled as PEG after evaluating fits for all 816 
components of the buffer.  817 
 818 
Cryo-EM sample preparation 819 
EBOV/Mak GPDmuc was incubated overnight with a 5-fold molar excess of each Fab at 820 
4°C. The complexes were then purified by SEC using an S200I column equilibrated in 1X TBS 821 
and concentrated using a 100-kDa concentrator (Amicon Ultra, Millipore) and mixed with 822 
detergent immediately prior to freezing (Table S2). Vitrification was performed with a Vitrobot 823 
(ThermoFisher Scientific) equilibrated to 4°C and 100% humidity. Cryo-EM grids were plasma 824 
cleaned for 5s using a mixture of Ar/O2 (Gatan Solarus 950 Plasma system) followed by blotting 825 
on both sides of the grid with filter paper (Whatman No. 1). See Table S1 for additional details for 826 
individual complexes. Note that ADI-15878 Fab was added to the BDBV-43 complex and ADI-827 
16061 Fab and EBOV-515 Fab was added to the EBOV-437, EBOV-442, EBOV-293, EBOV-828 
296, EBOV-237 and BDBV-329 complexes to assist in angular sampling and orientations in ice.  829 
 830 
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Cryo-EM data collection and processing 831 
 Cryo-EM data were collected according to Table S1. Micrographs were aligned and dose-832 
weighted using MotionCor2 (Zheng et al., 2017). CTF estimation was completed using GCTF 833 
(Zhang, 2016). Particle picking and initial 2D classification were initially performed using 834 
CryoSPARC 2.0 (Punjani et al., 2017) to clean up particle stacks and exclude any complexes that 835 
were degrading. For those reconstructions that required more extensive 3D classification, particle 836 
picks were then imported into Relion 3.1b1 (Zivanov et al., 2018) for 3D classification and then 837 
refinement using appropriate symmetry where necessary and a tight mask around the GP/Fab 838 
complex of interest. CTF refinement was then performed by either Relion or CryoSPARC to 839 
increase map quality and resolution. There was no density for ADI-16061 in any of the maps and 840 
we did not build density for ADI-15878 in the BDBV-43 map (this was previously deposited under 841 
PDB 6DZM). We chose not to build a model into EBOV-515 density but included this density in 842 
our reconstructions to assist with particle alignment. 843 
 844 
Cryo-EM model building and refinement 845 
 Homology models of Fab were first generated using SWISS-MODEL (Biasini et al., 2014). 846 
Models of BDBV GP (PDB: 6DZM) and EBOV GP (PDB: 5JQ3) were then added to generate 847 
starting models used for refinement. Models were fit into maps using UCSF Chimera (Pettersen et 848 
al., 2004) and refined initially using Phenix real-space refinement using NCS constraints 849 
(Liebschner et al., 2019). The refined model was then used as a template for relaxed refinement in 850 
Rosetta (DiMaio et al., 2015). The top five models were then evaluated for fit in EM density and 851 
adjusted manually using Coot (Emsley et al., 2010) to maximize fit. Finally, Man9 glycans were 852 
fit into glycan densities, trimmed and then a final refinement was performed in Rosetta. The final 853 
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structures were evaluated using EMRinger (Barad et al., 2015) and Molprobity from Phenix. All 854 
figures were generated in UCSF Chimera (Pettersen et al., 2004). Antibody contacts were analyzed 855 
using LigPlot (Laskowski and Swindells, 2011), Arpeggio (Jubb et al., 2017) and UCSF Chimera 856 
(Pettersen et al., 2004).  857 
 858 
Inferred germline antibody analysis 859 
 Inferred germline sequences for BDBV289 and BDBV43 FV domains were determined 860 
using IMGT/V-QUEST (Brochet et al., 2008; Giudicelli et al., 2011). Nucleotide sequences of B-861 
cells originally isolated from donors were kindly provided by James Crowe and used to derive a 862 
list of likely germline VDJ genes. Those with the highest confidence were then used to reconstruct 863 
an inferred germline sequence. The mature CDRH3 sequence was included in the reconstructed 864 
germline sequences due to low confidence in predicting germline CDRH3 sequences, although 865 
some residues were predicted to be different from the germline CDRH3. For BDBV-289 and 866 
BDBV-43, inferred germline sequences were then codon optimized for mammalian protein 867 
expression and sub-cloned into the appropriate AbVec expression vector. Stop codons were 868 
introduced as described above to produce Fab. 869 
 870 
QUANTIFICATION AND STATISTICAL ANALYSIS 871 
The descriptive statistics mean ± SEM or mean ± SD were determined for continuous 872 
variables as noted. EC50 values for mAb binding were determined after log transformation of 873 
antibody concentration using sigmoidal dose-response nonlinear regression analysis. Correlation 874 
between antibody synergy and percent monomer in GP trimer fraction was estimated using linear 875 
regression analysis. In neutralization assays, IC50 values were calculated after log transformation 876 
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of antibody concentrations using a 4-parameter nonlinear fit analysis. Technical and biological 877 
replicates are indicated in the figure legends. Statistical analyses were performed using Prism v8 878 
(GraphPad). 879 
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